Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
FSTX similar filings
- 4 Jan 21 F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
- 4 Dec 20 F-star Therapeutics Announces First Patient Dosed in First-in-Class
- 25 Nov 20 F-star Therapeutics Announces Clearance of
- 20 Nov 20 F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals
- 9 Nov 20 Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
- 12 Aug 20 Regulation FD Disclosure
- 10 Aug 20 Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results
Filing view
External links
Exhibit 16.1
November 20, 2020
Securities and Exchange Commission
Washington, D.C. 20549
Commissioners:
We have read Spring Bank Pharmaceuticals, Inc.’s statements included under Item 4.01(a) of its Form 8-K filed on November 20, 2020 and we agree with such statements concerning our firm.
/s/ RSM US LLP